6533b821fe1ef96bd127c4cb
RESEARCH PRODUCT
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
Anna FalangaHarlan M. KrumholzCaroline Der NigoghossianAlex C. SpyropoulosWalter AgenoYu HuJeffrey I. WeitzSam SchulmanGregg W. StoneDominic P. FranceseSamuel Z. GoldhaberSamuel Z. GoldhaberMohammad MadjidIdo WeinbergBehnood BikdeliSahil A. ParikhC. Michael GibsonC. Michael GibsonJohn W. EikelboomJohn W. EikelboomJay GiriGeoffrey D. BarnesManuel MonrealEvangelos DimakakosJoshua A. BeckmanGregory PiazzaGregory PiazzaMahesh V. MadhavanElizabeth Y. WangMary CushmanTaylor ChuichEmmanuel J. FavaloroP. Gabriel StegYutao GuoGiuseppe LippiElissa DrigginJoseph A. CapriniJawed FareedAlfonso TafurIsaac DreyfusJohn R. BurtonMarc CarrierIsabelle QuéréStephan RosenkranzStavros KonstantinidesDavid JiménezClaire MclintockGregory Y.h. LipGregory Y.h. LipLiang V. TangBeverley J. Huntsubject
medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular Medicinebusinessdescription
Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-06-01 | Journal of the American College of Cardiology |